NCT02852122View on ClinicalTrials.gov

The Role of C-11 Choline PET in Patients With Prostate Cancer

NACompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

January 31, 2015

Primary Completion Date

December 31, 2016

Study Completion Date

December 31, 2016

Conditions
Latent Cancer Prostate
Interventions
DRUG

C-11 choline

This is an uncontrolled, open-labeled, non-randomized, prospective study. The study duration is expected to be completed in a period of 2 years. Up to 54 patients with primary prostate cancer and stratified as high risk group (PSA \> 20 ng/mL, or Gleason score 8-10, or clinical stage \>T2c) would be included.

All Listed Sponsors
lead

Chang Gung Memorial Hospital

OTHER

NCT02852122 - The Role of C-11 Choline PET in Patients With Prostate Cancer | Biotech Hunter | Biotech Hunter